<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106050</url>
  </required_header>
  <id_info>
    <org_study_id>255NP101</org_study_id>
    <secondary_id>2019-001900-39</secondary_id>
    <nct_id>NCT04106050</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Parallel, Placebo- and Active-Controlled, Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A: Primary objective is to determine the effects of BIIB095 on nerve excitability in
      healthy participants. Secondary and exploratory objectives include determining the effects of
      BIIB095 on nerve excitability in diabetic polyneuropathy (DPN) and assessing the safety,
      tolerability and pharmacokinetics of BIIB095.

      Part B (optional): Equivalent objectives are pursued for BIIB074.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">January 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Compound Muscle Action Potential Threshold Tracking (CMAP-TT) in the Median Nerve of Healthy Participants</measure>
    <time_frame>Baseline (Day 1), Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sensory Nerve Excitability from Baseline (Day 1) to Last Treatment Visit (Day 8) as Determined by Sensory Nerve Action Potential Threshold Tracking (SNAP-TT) in the Median Nerve of Healthy Participants</measure>
    <time_frame>Baseline (Day 1), Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>AEs: Day 1 up to Day 22; SAEs: Screening up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to Time of the Last Measurable Concentration (AUClast)</measure>
    <time_frame>Pre-dose, 1 hour (h), 1.5h, 3h, 6h and 8h post-dose on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve within a Dosing Interval (AUCtau)</measure>
    <time_frame>Pre-dose, 1 hour (h), 1.5h, 3h, 6h and 8h post-dose on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Pre-dose, 1 hour (h), 1.5h, 3h, 6h and 8h post-dose on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough)</measure>
    <time_frame>Pre-dose, 1 hour (h), 1.5h, 3h, 6h and 8h post-dose on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Pre-dose, 1 hour (h), 1.5h, 3h, 6h and 8h post-dose on Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Part A: BIIB095 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 1 capsules from Day 1 to Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BIIB095 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 2 capsules from Day 1 to Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BIIB095 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of BIIB095 Dose 3 capsules from Day 1 to Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BIIB095 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB095 capsules from Day 1 to Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy participants and participants with DPN will receive single injection of lidocaine for partial nerve conduction block and single injection of lidocaine for skin infiltration on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BIIB074 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of BIIB074 Dose 1 tablets from Day 1 to Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BIIB074 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants and participants with DPN will receive oral dose of placebo matching BIIB074 tablets from Day 1 to Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB095</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part A: BIIB095 Dose 1</arm_group_label>
    <arm_group_label>Part A: BIIB095 Dose 2</arm_group_label>
    <arm_group_label>Part A: BIIB095 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB074</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part B: BIIB074 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part A: BIIB095 Placebo</arm_group_label>
    <arm_group_label>Part B: BIIB074 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Part A: Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy participants must be in good health, as determined based on medical history
             and screening evaluations

          -  Participants with DPN

               -  Must have a documented diagnosis of type 2 diabetes mellitus (DM)

               -  Must have stable glycemic control

               -  Must have at least clinical evidence of painful DPN

               -  Pain related to DPN must be present for at least 6 months prior to screening

               -  Average daily pain intensity over 7 consecutive days recorded during screening
                  must be â‰¥ 4 on an 11-point numerical rating scale ranging from 0 (no pain) to 10
                  (worst pain imaginable)

        Key Exclusion Criteria:

          -  Any neurologic or painful condition that could confound the interpretation of study
             results

          -  History of any clinically significant cardiac, hematologic, hepatic, immunologic,
             urologic, pulmonary, dermatologic, psychiatric, renal, or other major disease. This
             includes any clinically significant endocrinologic or neurologic disease other than DM
             or DPN.

          -  Use of local anesthetics or capsaicin for topical or regional treatment within 3
             months prior to Screening.

          -  Systemic use of sodium channel inhibitors

        Note: Other protocol-specific inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

